Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis

Overview of attention for article published in Familial Cancer, February 2016

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 19 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 9 publications that cite this research output.

9

The most recent citing publications are shown below. View all 9 publications that cite this research output on Dimensions.

Olaparib plus bevacizumab as a first-line maintenance treatment for patients with advanced ovarian cancer by molecular status: an updated PAOLA-1 based cost-effectiveness analysis

Article in Journal of Gynecologic Oncology (January 2024)

The cost-effectiveness analysis of maintenance olaparib plus Bevacizumab in patients with advanced ovarian cancer: based on the final survival results from PAOLA-1 trial

Article in Journal of Ovarian Research (August 2023)

Comparison of Survival Outcomes According to BRCA1/2 Variant Type in High-grade Serous Ovarian Cancer

Article in In Vivo (June 2022)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.